Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05577000 · ClinicalTrials.gov registry record · Phase 1
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Thomas Martin, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05577000 is a Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma that is active but no longer recruiting, run by Thomas Martin, MD. The registered enrollment target is 5 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05577000, a Phase 1 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, is active but no longer recruiting, sponsored by Thomas Martin, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Manufactured Anti-BCMA CAR-T cells
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2038-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05577000
The ClinicalTrials.gov registry entry for NCT05577000 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is Thomas Martin, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05577000 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05577000 about?
NCT05577000 is a clinical study titled "Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma". This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).
What is the current status of trial NCT05577000?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-10-18. Estimated completion is 2038-08-31.
What conditions does trial NCT05577000 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma.
What interventions are being tested in trial NCT05577000?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Manufactured Anti-BCMA CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05577000?
This trial is sponsored by Thomas Martin, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05577000 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.